دورية أكاديمية
Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility
| العنوان: | Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility |
|---|---|
| المؤلفون: | Serena Valsami, Dimitrios Dimitroulis, Argyri Gialeraki, Maria Chimonidou, Marianna Politou |
| المصدر: | Asian Journal of Transfusion Science, Vol 9, Iss 2, Pp 117-123 (2015) |
| بيانات النشر: | Wolters Kluwer Medknow Publications, 2015. |
| سنة النشر: | 2015 |
| المجموعة: | LCC:Diseases of the blood and blood-forming organs |
| مصطلحات موضوعية: | ABO-incompatibility, human leukocyte antigen-platelet refractoriness, platelet transfusion, RhD, Diseases of the blood and blood-forming organs, RC633-647.5 |
| الوصف: | Platelet transfusions have contributed to the revolutionary modern treatment of hypoproliferative thrombocytopenia. Despite the long-term application of platelet transfusion in therapeutics, all aspects of their optimal use (i.e., in cases of ABO and/or Rh (D incompatibility) have not been definitively determined yet. We reviewed the available data on transfusion practices and outcome in ABO and RhD incompatibility and platelet refractoriness due to anti-human leukocyte antigen (HLA) antibodies. Transfusion of platelets with major ABO-incompatibility is related to reduced posttransfusion platelet (PLT) count increments, compared to ABO-identical and minor, but still are equally effective in preventing clinical bleeding. ABO-minor incompatible transfusions pose the risk of an acute hemolytic reaction of the recipient that is not always related to high anti-A, B donor titers. ABO-identical PLT transfusion seems to be the most effective and safest therapeutic strategy. Exclusive ABO-identical platelet transfusion policy could be feasible, but alternative approaches could facilitate platelet inventory management. Transfusion of platelets from RhD positive donors to RhD negative patients is considered to be effective and safe though is associated with low rate of anti-D alloimmunization due to contaminating red blood cells. The prevention of D alloimmunization is recommended only for women of childbearing age. HLA alloimmunization is a major cause of platelet refractoriness. Managing patients with refractoriness with cross-matched or HLA-matched platelets is the current practice although data are still lacking for the efficacy of this practice in terms of clinical outcome. Leukoreduction contributes to the reduction of both HLA and anti-D alloimmunization. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0973-6247 1998-3565 |
| Relation: | http://www.ajts.org/article.asp?issn=0973-6247;year=2015;volume=9;issue=2;spage=117;epage=123;aulast=Valsami; https://doaj.org/toc/0973-6247; https://doaj.org/toc/1998-3565 |
| DOI: | 10.4103/0973-6247.162684 |
| URL الوصول: | https://doaj.org/article/1fb221ef0f5c4423bf6bc2f0e8173e03 |
| رقم الأكسشن: | edsdoj.1fb221ef0f5c4423bf6bc2f0e8173e03 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 09736247 19983565 |
|---|---|
| DOI: | 10.4103/0973-6247.162684 |